

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 69538

Title: Therapeutic potentials of fasudil in liver fibrosis

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02445404 Position: Peer Reviewer

Academic degree: PhD

Professional title: Dean, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United States

Manuscript submission date: 2021-07-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-07-05 00:30

Reviewer performed review: 2021-07-14 06:43

Review time: 9 Days and 6 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer	Peer-Review: [] Anonymous [Y] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com **https:**//www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

This "letter to the editor" supplemented the ongoing discussion on the therapeutic potentials of Fasudil in the treatment of hepatic fibrosis. Authors mainly make comments about the recent basic study and other studies. The view that Fasudi is a promising medication for the prevention and treatment of liver fibrosis is concluded based several solid basic studies. The comments in this letter are objective and serious.